3

NCT02438787 – A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Ustekinumab in the Treatment of Anti-TNF (Alpha) Refractory Subjects With Active Radiographic Axial Spondyloarthritis

Posted on November 9, 2018 by tsuperadmin -

NCT02437162 – A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Ustekinumab in the Treatment of Anti-TNF Alpha Naive Subjects With Active Radiographic Axial Spondyloarthritis

Posted on November 9, 2018 by tsuperadmin -

NCT01106014 – A Multicenter, Double-blind, Placebo-controlled Phase 3 Study Assessing the Safety and Efficacy of Selexipag on Morbidity and Mortality in Patients With Pulmonary Arterial Hypertension

Posted on October 23, 2018 by tsuperadmin -

NCT00391443 – Effects of Bosentan on Morbidity and Mortality in Patients With Idiopathic Pulmonary Fibrosis – a Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Event-driven, Group Sequential, Phase III Study

Posted on September 10, 2018 by tsuperadmin -

NCT01962974 – A Golimumab Phase 3b, Multicenter, Assessment of Intravenous Efficacy in Rheumatoid Arthritis Subjects Who Have Diminished Disease Control Despite Treatment With Infliximab (REMICADE®)

Posted on August 6, 2018 by tsuperadmin -

NCT01863771 – A Safety and Effectiveness Study of Golimumab in Japanese Patients With Moderately to Severely Active Ulcerative Colitis

Posted on August 6, 2018 by tsuperadmin -

NCT01004432 – Golimumab in Rheumatoid Arthritis Participants With an Inadequate Response to Etanercept (ENBREL) or Adalimumab (HUMIRA)

Posted on August 6, 2018 by tsuperadmin -

NCT02181673 – A Study of Golimumab in Participants With Active Psoriatic Arthritis

Posted on August 6, 2018 by tsuperadmin -

NCT01230827 – A Study of the Safety and Efficacy of CNTO 148 (Golimumab) in Children With Juvenile Idiopathic Arthritis (JIA) and Multiple Joint Involvement Who Have Poor Response to Methotrexate (GO KIDS)

Posted on August 6, 2018 by tsuperadmin -

NCT01090427 – A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the of Efficacy and Safety of Ustekinumab in the Treatment of Adolescent Subjects With Moderate to Severe Plaque-type Psoriasis (CADMUS)

Posted on July 3, 2018 by tsuperadmin -